BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20870446)

  • 1. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.
    Jokinen P; Scheinin N; Aalto S; Någren K; Savisto N; Parkkola R; Rokka J; Haaparanta M; Röyttä M; Rinne JO
    Parkinsonism Relat Disord; 2010 Dec; 16(10):666-70. PubMed ID: 20870446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.
    González-Redondo R; García-García D; Clavero P; Gasca-Salas C; García-Eulate R; Zubieta JL; Arbizu J; Obeso JA; Rodríguez-Oroz MC
    Brain; 2014 Aug; 137(Pt 8):2356-67. PubMed ID: 24951642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia.
    Edison P; Ahmed I; Fan Z; Hinz R; Gelosa G; Ray Chaudhuri K; Walker Z; Turkheimer FE; Brooks DJ
    Neuropsychopharmacology; 2013 May; 38(6):938-49. PubMed ID: 23303049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).
    Nobili F; Morbelli S; Arnaldi D; Ferrara M; Campus C; Brugnolo A; Mazzei D; Mehrdad N; Sambuceti G; Rodriguez G
    J Neurol Sci; 2011 Nov; 310(1-2):31-5. PubMed ID: 21762928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson's disease.
    Low A; Foo H; Yong TT; Tan LCS; Kandiah N
    J Neurol Neurosurg Psychiatry; 2019 Jun; 90(6):681-687. PubMed ID: 30683708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.
    Bohnen NI; Koeppe RA; Minoshima S; Giordani B; Albin RL; Frey KA; Kuhl DE
    J Nucl Med; 2011 Jun; 52(6):848-55. PubMed ID: 21571793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
    Buongiorno M; Compta Y; Martí MJ
    J Neurol Sci; 2011 Nov; 310(1-2):25-30. PubMed ID: 21764078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
    Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
    Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease.
    Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Suzuki K; Hasegawa T; Aoki M; Takeda A; Mori E
    J Neurol Sci; 2017 Jan; 372():288-293. PubMed ID: 28017230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [11C]PIB binding in Parkinson's disease dementia.
    Maetzler W; Reimold M; Liepelt I; Solbach C; Leyhe T; Schweitzer K; Eschweiler GW; Mittelbronn M; Gaenslen A; Uebele M; Reischl G; Gasser T; Machulla HJ; Bares R; Berg D
    Neuroimage; 2008 Feb; 39(3):1027-33. PubMed ID: 18035558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease.
    Garcia-Garcia D; Clavero P; Gasca Salas C; Lamet I; Arbizu J; Gonzalez-Redondo R; Obeso JA; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1767-77. PubMed ID: 22872307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
    Jokinen P; Brück A; Aalto S; Forsback S; Parkkola R; Rinne JO
    Parkinsonism Relat Disord; 2009 Feb; 15(2):88-93. PubMed ID: 18434233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease.
    Blum D; la Fougère C; Pilotto A; Maetzler W; Berg D; Reimold M; Liepelt-Scarfone I
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2387-2395. PubMed ID: 30008111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
    Vallabhajosula S
    Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in
    Wu L; Liu FT; Ge JJ; Zhao J; Tang YL; Yu WB; Yu H; Anderson T; Zuo CT; Chen L; Wang J
    Hum Brain Mapp; 2018 Dec; 39(12):4652-4662. PubMed ID: 29999569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.
    Brück A; Virta JR; Koivunen J; Koikkalainen J; Scheinin NM; Helenius H; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1567-72. PubMed ID: 23801168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of brain MRI and 18F-FDG PET in the differentiation of Parkinsonian-type multiple system atrophy from Parkinson's disease.
    Kwon KY; Choi CG; Kim JS; Lee MC; Chung SJ
    Eur J Neurol; 2008 Oct; 15(10):1043-9. PubMed ID: 18717730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.